Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
Phase 1
Completed
- Conditions
- Locally Recurrent and Metastatic Breast Cancer
- Interventions
- Registration Number
- NCT00322400
- Lead Sponsor
- Amgen
- Brief Summary
This open-label, dose-finding, multi-center study is designed to determine the safety and the maximum tolerated dose of AMG 706 given once daily in combination with either weekly paclitaxel (Arm A) or once-every-3 week docetaxel (Arm B) in subjects with locally recurrent or metastatic breast cancer. Secondarily, this study will evaluate the pharmacokinetic (PK) profile of AMG 706 in both treatment arms, the PK profile of paclitaxel in Arm A and the PK profile of docetaxel in Arm B. Additionally, this study will assess objective tumor response and duration of response. Exploratory endpoints include the investigation of potential biomarker development and to assess the effects of genetic variation in drug metabolism genes, cancer genes and drug target genes on subject response to AMG 706 in combination with paclitaxel or docetaxel.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 46
Inclusion Criteria
- Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Female 18 years of age or older.
- Adequate hematologic, renal and hepatic function.
- Competent to comprehend, sign, and date an IRB-approved informed consent form.
- Subjects of childbearing potential and sexually active must provide a negative pregnancy test and use accepted and effective method of contraception.
Exclusion Criteria
- Prior taxane-containing treatment within 6 months prior to enrollment.
- Prior treatment including chemotherapy and/or endocrine therapy discontinued < 21 days prior to enrollment.
- More than one prior systemic chemotherapy for locally recurrent or metastatic breast cancer.
- Current or prior history of central nervous system metastases.
- History of arterial or venous thrombosis within 1 year prior to enrollment.
- History of bleeding diathesis or bleeding within 14 days prior to enrollment.
- Radiation therapy to a significant portion of bone marrow or prior history of high-dose chemotherapy requiring bone marrow or stem cell support.
- Hypersensitivity to paclitaxel, docetaxel, or drugs using the vehicle cremophor.
- Prior VEGFr targeted therapies within 30 days of enrollment.
- Any anticoagulant therapy within 7 days prior to enrollment, except for warfarin of less than 2mg per day.
- Clinically significant cardiac disease including myocardial infarction or other cardiovascular related event within 1 year before enrollment.
- Uncontrolled hypertension (systolic >150 mmHg; diastolic > 90 mmHg).
- Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive.
- Prior bevacizumab or trastuzumab therapy within 12 weeks of enrollment.
- Non-healing wound, ulcer or fracture.
- Known history of prior episodes of cholecystitis, prior biliary procedure or prior or ongoing biliary disease.
- Unable to take oral medications.
- Not recovered from previous therapies.
- Major surgery within 28 days prior to enrollment.
- Prior malignancy unless treated with curative intent and without evidence of disease for greater than 3 years before enrollment.
- Peripheral neuropathy grade > 1 per CTCAE version 3.0
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description B1 AMG 706 AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days) A4 AMG 706 75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days) A1 AMG 706 AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days) B4 AMG 706 75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days) B5 AMG 706 MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days) B3 AMG 706 100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days) B2 AMG 706 AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days) A2 AMG 706 AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days A3 AMG 706 100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days) B1 Docetaxel AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days) A4 Paclitaxel 75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days) A1 Paclitaxel AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days) B4 Docetaxel 75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days) B5 Docetaxel MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days) B3 Docetaxel 100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days) B2 Docetaxel AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days) A2 Paclitaxel AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days A3 Paclitaxel 100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days)
- Primary Outcome Measures
Name Time Method Incidence of dose limiting toxicities (DLTs) Cycle 1 of treatment. For Arm A, 1 cycle = 28 days. For Arm B, 1 cycle = 21 days
- Secondary Outcome Measures
Name Time Method Pharmacokinetics of AMG 706 when administered with paclitaxel (Arm A) or docetaxel (Arm B) Cycle 1 (Arms A and B) and Cycle 2 Arm B only) Pharmacokinetics of paclitaxel (Arm A) when administered with AMG 706 Cycle 1, D1 and D8 for subjects in Arm A only Pharmacokinetics of docetaxel (Arm B) when administered with AMG 706 Cycles 1 and 2 for subjects in Arm B only Incidence of adverse events and clinical laboratory abnormalities not defined as DLTs From study entry through 30 days post discontinuation of study treatment Objective tumor response (complete or partial response) according to modified RECIST Subjects in Arm A: every 8 weeks until discontuation. Subjects in Arm B:every 6 weeks until discontinuation. Duration of response (calculated for those subjects who respond): time from first objective tumor response to objective disease progression or death. Subjects in Arm A: every 8 weeks until discontuation. Subjects in Arm B:every 6 weeks until discontinuation.